Effect of platelet-rich plasma therapy in rheumatoid arthritis

Phase 3

Recruiting

• Conditions: Rheumatoid arthritis (RA).; Other rheumatoid arthritis

• Registration Number: IRCT20221203056694N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

This study will be done on 40 patients with RA diseases who were diagnosed at the rheumatology clinic of Hafez Hospital, according to the American College of Rheumatology/European League Against Rheumatism criteria.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Erythrocyte Sedimentation Rate (ESR). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: Westergren method.;C-reactive protein (CRP). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Anti Citrullinated peptide Antibody. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Antinuclear Antibody (ANA). Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Rheumatoid Arthritis (RA) factor. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Interleukin-1 beta. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: ELISA.;Radiological Examination. Timepoint: Before and after Platelet-rich plasma (PRP) therapy. Method of measurement: Radiology.